Loading
Champions Oncology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Jan 2024.
Champions Oncology, Inc.: what insiders have been doing
Champions Oncology, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Champions Oncology, Inc. logged 2 filings by 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of Champions Oncology, Inc. stock was filed.
Compared with its exchange (5,814 companies, median 19 filings), a count of 2 filings is below the norm. The full history, which starts in 2021, counts 26 purchases against no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
37
Thresholds
n/a
Buy Volume
€459,875
26 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +35.3%Entry US$6.78 · Close at T+365 US$9.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,315 of 24,148 companies
24.0
score / 100
Value22
Quality26
FCF yld-7.7%
Earn yld-1.8%
EV/EBITDA·
ROE-28%
Gross mgn48%
Net mgn-2.0%
Debt/EBITDA13.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended April 2026 · cache
US$5.08
Analyst consensus
Income statement
RevenueUS$59.4M
Gross profitUS$28.5M48% margin
EBITDAUS$348k1% margin
Net income-US$1.2M-2.0% margin
Valuation
P/Book17.9x
Beta0.41
Balance sheet & cash
Market capUS$70.6M
Total debtUS$4.5M
Free Cash Flow-US$5M
Debt / Equity113%
Profitability & ownership
ROE-30.0%
ROA-2.2%
% insiders26.7%
% institutions41.2%
Last declaration on 16 October 2026
Declarations37 total
69,794 shares@ US$1.60Common StockSEC:0001628280-26-066091:0
94,405 shares@ US$2.1027.4% of flowCommon StockSEC:0001628280-25-049954:0
4,150 shares0Common StockSEC:0001628280-25-016197:0
88,470 shares@ US$2.1027.4% of flowCommon StockSEC:0001628280-24-044663:0
1,000 shares@ US$6.501.4% of flowCommon StockSEC:0001628280-24-001334:0
Canonical exit: 11 Apr 2024 (T+90)
2,000 shares@ US$6.272.8% of flowCommon StockSEC:0001628280-24-001231:0
Canonical exit: 10 Apr 2024 (T+90)
2,944 shares@ US$6.314.1% of flowCommon StockSEC:0001628280-24-001118:0
Canonical exit: 9 Apr 2024 (T+90)
3,000 shares@ US$6.254.1% of flowCommon StockSEC:0001628280-24-001002:0
Canonical exit: 8 Apr 2024 (T+90)
1,000 shares@ US$6.151.4% of flowCommon StockSEC:0001628280-24-000896:0
Canonical exit: 7 Apr 2024 (T+90)
2,000 shares@ US$6.092.7% of flowCommon StockSEC:0001628280-24-000825:0
Canonical exit: 4 Apr 2024 (T+90)
3,000 shares@ US$6.124.1% of flowCommon StockSEC:0001628280-24-000820:0
Canonical exit: 3 Apr 2024 (T+90)
114,552 shares@ US$2.1036.4% of flowCommon StockSEC:0001628280-24-000639:0
500 shares@ US$5.830.6% of flowCommon StockSEC:0001628280-24-000388:0
Canonical exit: 2 Apr 2024 (T+90)
2,500 shares@ US$4.922.7% of flowCommon StockSEC:0001628280-23-042662:0
Canonical exit: 20 Mar 2024 (T+90)
2,100 shares@ US$4.822.2% of flowCommon StockSEC:0001628280-23-042467:0
Canonical exit: 19 Mar 2024 (T+90)
5,000 shares@ US$4.755.3% of flowCommon StockSEC:0001628280-23-042096:0
Canonical exit: 18 Mar 2024 (T+90)
5,000 shares@ US$6.227.1% of flowCommon StockSEC:0001628280-23-034407:0
Canonical exit: 27 Dec 2023 (T+90)
4,000 shares@ US$6.165.7% of flowCommon StockSEC:0001628280-23-034409:0
Canonical exit: 28 Dec 2023 (T+90)
1,500 shares@ US$5.952.1% of flowCommon StockSEC:0001628280-23-034405:0
Canonical exit: 26 Dec 2023 (T+90)
5,000 shares@ US$6.407.3% of flowCommon StockSEC:0001628280-23-034348:0
Canonical exit: 9 Jan 2024 (T+90)
1,100 shares@ US$6.411.6% of flowCommon StockSEC:0001628280-23-034231:0
Canonical exit: 8 Jan 2024 (T+90)
1,530 shares@ US$6.482.3% of flowCommon StockSEC:0001628280-23-034119:0
Canonical exit: 4 Jan 2024 (T+90)
2,000 shares@ US$6.473.0% of flowCommon StockSEC:0001628280-23-034004:0
Canonical exit: 3 Jan 2024 (T+90)
5,000 shares@ US$6.407.4% of flowCommon StockSEC:0001628280-23-033842:0
Canonical exit: 2 Jan 2024 (T+90)
2,500 shares@ US$6.303.6% of flowCommon StockSEC:0001628280-23-033843:0
Canonical exit: 1 Jan 2024 (T+90)
25 of 37 declarations
About Champions Oncology, Inc.
Champions Oncology, Inc. (ticker: CSBR) is a United States-based company listed on the Nasdaq market in the United States, focused on translational oncology and research services for biopharmaceutical clients. Headquartered in Hackensack, New Jersey, the company has built a niche position around helping pharma and biotech partners better understand tumor biology, treatment response, and resistance mechanisms earlier in the drug-development cycle. Its roots date back to the late 1990s, and over time the business has evolved from a tumor-model platform into a broader oncology solutions provider combining preclinical research, clinical support, and data monetization.
The company’s core franchise is centered on patient-derived xenograft (PDX) models, in which human tumors are implanted into immunodeficient mice to better replicate how cancers behave in patients. Champions Oncology operates one of the industry’s largest and most highly annotated PDX model banks and offers integrated in vivo and ex vivo workflows. Its main business lines include drug discovery and optimization support, translational pharmacology studies, clinical bioanalytical services, and an emerging data licensing business built on multiomic and functionally annotated tumor datasets.
Read moreShow less
From a competitive standpoint, Champions occupies a specialized but relevant position among oncology research providers. It is differentiated less by scale than by scientific depth, clinical relevance, and the ability to generate actionable data earlier in development. That makes it attractive to biopharma customers seeking to reduce translational risk and make better pipeline decisions. The company also maintains research operations in the United States and a bioinformatics/computational biology presence in Israel, strengthening its data-oriented capabilities.
Recent milestones have been important. In 2025, Champions Oncology reported record revenue, improved profitability, and a clear push toward growth in higher-margin data and platform services. The company also launched a radiopharmaceutical services platform, expanded its isotope-related capabilities, and continued to present new scientific data at major industry meetings such as AACR 2026. For investors, CSBR is a small-cap Nasdaq-listed healthcare name with exposure to biotech spending cycles, but also with a differentiated platform in precision oncology and translational research.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
